The DOI matches its Crossref record; 248 of the 248 references it cites were found in a registry or an index.
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–248 of 248
Slingerland, M., Guchelaar, H., Rosing, H., Scheulen, M. E., van Warmerdam, L. J. C., Beijnen, J. H., & Gelderblom, H. A. J. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.10.009 · Cited by 89
Soepenberg, O., Dumez, H., Verweij, J., de Jong, F. A., de Jonge, M. J. A., Thomas, J., Eskens, F. A. L. M., van Schaik, R. H. N., Selleslach, J., ter Steeg, J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1758 · Cited by 88
Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery
Pecorelli, T. A., Dibrell, M. M., Li, Z., Thomas, C. R., & Zink, J. I. (2010) · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · doi:10.1117/12.841168 · Cited by 84
Dicheva, B. M., & Koning, G. A. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.866650 · Cited by 83
Gonzalez-Angulo, A. M., Meric‐Bernstam, F., Chawla, S. P., Falchook, G. S., Hong, D. S., Akçakanat, A., Chen, H., Naing, A., Fu, S., Wheler, J. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3110 · Cited by 82
The Thymidine Kinase/Ganciclovir-Mediated “Suicide” Effect Is Variable in Different Tumor Cells
Beck, C., Cayeux, S., Lupton, S. D., Dörken, B., & Blankenstein, T. J. F. (1995) · Human Gene Therapy · doi:10.1089/hum.1995.6.12-1525 · Cited by 82
Awada, A. H., García, A. A., Chan, S. Y. T., Jérusalem, G., Coleman, R. E., Huizing, M. T., Mehdi, A., O'Reilly, S. M., Hamm, J. T., Barrett-Lee, P. J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70429-7 · Cited by 80
Pal, A., Khan, S., Wang, Y.-F., Kamath, N., Sarkar, A., Ahmad, A., Sheikh, S., Ali, S., Carbonaro, D., Zhang, A., et al. (2005) · PubMed · Cited by 79
Scott, L. C., Yao, J. C., Benson, A. B., Thomas, A., Falk, S. J., Mena, R. R., Picus, J., Wright, J. R., Mulcahy, M. F., Ajani, J. A., et al. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0746-2 · Cited by 78
Deeken, J. F., Slack, R. S., Weiss, G. J., Ramanathan, R. K., Pishvaian, M. J., Hwang, J. J., Lewandowski, K., Subramaniam, D. S., He, A. R., Cotarla, I., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2048-y · Cited by 78
Vile, R. G., Ando, D. G., & Kirn, D. H. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700548 · Cited by 78
Gaur, S., Wang, Y., Kretzner, L., Chen, L., Yen, T., Wu, X., Yuan, Y., Davis, M. E., & Yen, Y. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2014.04.003 · Cited by 77
Targeted Expression of BikDD Eradicates Pancreatic Tumors in Noninvasive Imaging Models
Xie, X., Xia, W., Li, Z., Kuo, H.-P., Liu, Y., Li, Z., Ding, Q., Zhang, S., Spohn, B., Yang, Y., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.009 · Cited by 77
Bolling, C., Graefe, T., Lübbing, C., Jankevičius, F., Uktveris, S., Česas, A., Meyer‐Moldenhauer, W., Starkmann, H., Weigel, M. T., Burk, K., et al. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-8221-6 · Cited by 77
Jung, J., Park, S. J., Chung, H. K., Kang, H.-W., Lee, S.-W., Seo, M. H., Park, H. J., Song, S. Y., Jeong, S., & Choi, E. K. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.02.030 · Cited by 75
Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors
Soepenberg, O., de Jonge, M. J. A., Sparreboom, A., de Bruin, P. C., Eskens, F. A. L. M., de Heus, G., Wanders, J., Cheverton, P., Ducharme, M. P., & Verweij, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.703.11.2 · Cited by 75
Hamaguchi, T., Matsumura, Y., Nakanishi, Y., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Niki, H., Hosokawa, S., Tagawa, T., et al. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb02495.x · Cited by 74
The theranostic path to personalized nanomedicine
Theek, B., Rizzo, L. Y., Ehling, J., Kiessling, F. M., & Lammers, T. (2014) · Clinical and Translational Imaging · doi:10.1007/s40336-014-0051-5 · Cited by 74
Development of Porous Silicon Nanocarriers for Parenteral Peptide Delivery
Kovalainen, M., Mönkäre, J., Kaasalainen, M. H., Riikonen, J., Lehto, V., Salonen, J., Herzig, K., & Järvinen, K. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300494p · Cited by 74
Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density-dependent manner
Hosokawa, S., Tagawa, T., Niki, H., Hirakawa, Y., Nohga, K., & Nagaike, K. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601341 · Cited by 72
Ueno, T., Endo, K., Hori, K., Ozaki, N., Tsuji, A., Kondo, S., Wakisaka, N., Murono, S., Kataoka, K., Kato, Y., et al. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s60564 · Cited by 69
Gökbuget, N., Hartog, C.-M., Bassan, R., Derigs, H. G., Dombret, H., Greil, R., Hernández‐Rivas, J. M., Huguet, F., Intermesoli, T., Jourdan, É., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.028092 · Cited by 69
Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer
Booser, D. J., Esteva, F. J., Rivera, E., Valero, V., Esparza-Guerra, L., Priebe, W., & Hortobágyi, G. N. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0464-0 · Cited by 67
Preparation, Characterization, and Stability of Liposome-Based Formulations of Mitoxantrone
Ugwu, S. O., Zhang, A. W., Parmar, M. M., Miller, B., Sardone, T., Peikov, V. T., & Ahmad, I. (2005) · Drug Development and Industrial Pharmacy · doi:10.1081/ddc-200047850 · Cited by 61
Nanoparticles as delivery carriers for anticancer prodrugs
Fang, J., & Al‐Suwayeh, S. A. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.679927 · Cited by 60
Knockdown of β-catenin with Dicer-Substrate siRNAs Reduces Liver Tumor Burden In vivo
Dudek, H., Wong, D. H., Arvan, R., Shah, A., Wortham, K. A., Ying, B., Diwanji, R., Zhou, W. L., Holmes, B. R., Yang, H., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.233 · Cited by 57
Pirollo, K. F., Rait, A. S., Zhou, Q., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1951 · Cited by 56
Patnaik, A., Papadopoulos, K. P., Tolcher, A. W., Beeram, M., Urien, S., Schaaf, L. J., Tahiri, S., Bekaii‐Saab, T., Lokiec, F. M., Rezaï, K., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2149-2 · Cited by 54
Victories and deceptions in tumor immunology
Kroemer, G., Zitvogel, L., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23687 · Cited by 54
Madaan, A., Singh, P., Awasthi, A., Verma, R., Singh, A. T., Jaggi, M., Mishra, S. K., Kulkarni, S., & Kulkarni, H. S. (2012) · Clinical & Translational Oncology · doi:10.1007/s12094-012-0883-2 · Cited by 52
Mamot, C., Ritschard, R., WICKI, A. N., Küng, W., Schuller, J. C., Herrmann, R., & Rochlitz, C. F. (2012) · Journal of drug targeting · doi:10.3109/1061186x.2012.680960 · Cited by 52
Self-citationBoorjian, S. A., Milowsky, M. I., Kaplan, J., Albert, M., Cobham, M. V., Coll, D. M., Mongan, N. P., Shelton, G., Petrylak, D. P., Gudas, L. J., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31805449a8 · Cited by 52
Infante, J. R., Keedy, V. L., Jones, S. F., Zamboni, W. C., Chan, E. W., Bendell, J. C., Lee, W., Wu, H., Ikeda, S., Kodaira, H., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1960-5 · Cited by 49
Emerging classes of armed antibody therapeutics against cancer
Hess, C., Venetz, D., & Neri, D. (2014) · MedChemComm · doi:10.1039/c3md00360d · Cited by 49
Switching the Targeting Pathways of a Therapeutic Antibody by Nanodesign
Bhattacharyya, S., Singh, R. D., Pagano, R. E., Robertson, J. D., Bhattacharya, R., & Mukherjee, P. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201105432 · Cited by 44
A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor
Yang, S., Lin, C., Lin, Z., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9522-3 · Cited by 43
Veltkamp, S. A., Witteveen, E. O., Capriati, A., Crea, A., Animati, F., Voogel-Fuchs, M., van den Heuvel, I. J. G. M., Beijnen, J. H., Voest, E. E., & Schellens, J. H. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0438 · Cited by 43
Krivak, T. C., Smith, A. L., Zorn, K. K., Sukumvanich, P., Olawaiye, A. B., Kelley, J. L., & Berger, J. L. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s62881 · Cited by 42
Fortuin, A. S., Meijer, H. J. M., Thompson, L. C., Witjes, J. A., & Barentsz, J. O. (2013) · European Urology · doi:10.1016/j.eururo.2013.08.017 · Cited by 38
Arlinghaus, R. B., Lopez‐Berestein, G., Belmont, J. W., Rosenblum, M. G., Sun, T., Stephens, C. L., Monaco, G., Gutiérrez-Puente, Y., & Tari, A. M. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.5.1243 · Cited by 38
Hoff, D. D. V., Ervin, T. J., Arena, F. P., Chiorean, E. G., Infante, J. R., Moore, M. J., Seay, T. E., Tjulandin, S., Ma, W. W., Saleh, M. N., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.4005 · Cited by 38
Venkatakrishnan, K., Liu, Y., Noe, D. A., Mertz, J., Bargfrede, M., Marbury, T. C., Farbakhsh, K., Oliva, C., & Milton, A. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12260 · Cited by 35
Hedgire, S., Mino-Kenudson, M. A., Elmi, A., Thayer, S. P., Castillo, C. F. F.-D., & Harisinghani, M. G. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s59788 · Cited by 35
Armed antibodies for cancer treatment: a promising tool in a changing era
Danielli, R., Patuzzo, R., Ruffini, P. A., Maurichi, A., Giovannoni, L., Elia, G., Neri, D., & Santinami, M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1621-0 · Cited by 34
Hepatocyte targeting using pegylated asialofetuin-conjugated liposomes
Detampel, P., Witzigmann, D., Krähenbühl, S., & Huwyler, J. (2013) · Journal of drug targeting · doi:10.3109/1061186x.2013.860982 · Cited by 33
Self-citationVenkatakrishnan, K., Liu, Y., Noe, D. A., Mertz, J., Bargfrede, M., Marbury, T. C., Farbakhsh, K., Oliva, C., & Milton, A. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12261 · Cited by 31
Beutel, G., Glen, H., Schöffski, P., Chick, J., Gill, S., Cassidy, J., & Twelves, C. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0104 · Cited by 28
Ghamande, S. A., Lin, C., Cho, D. C., Shapiro, G. I., Kwak, E. L., Silverman, M. H., Tseng, Y., Kuo, M.-W., Mach, W. B., Hsu, S.-C., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0044-7 · Cited by 25
Cited by
Nano based drug delivery systems: recent developments and future prospects
Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., et al. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0392-8 · Cited by 6,684
Zhang, X.-F., Liu, Z.-G., Shen, W., & Gurunathan, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091534 · Cited by 3,220
Liposomal Formulations in Clinical Use: An Updated Review
Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9020012 · Cited by 2,156
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Block copolymer micelles in nanomedicine applications
Cabral, H., Miyata, K., Osada, K., & Kataoka, K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00199 · Cited by 1,309
Metadata
- Authors
- Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 200
- Pages
- 138-157
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2013765163
- Cited by
- 1,901
- References
- 248
- FWCI
- 43.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.